Follistatin and Ovarian Reserve Research: Follicle Biology, AMH and Reproductive Ageing UK 2026

Research Use Only. Not for human use. All content on this page relates strictly to preclinical and in vitro research findings.

Follistatin — the activin-binding glycoprotein produced across multiple tissues including the ovary, pituitary and liver — plays a critical regulatory role in ovarian follicle development through its modulation of activin and BMP (Bone Morphogenetic Protein) signalling within the follicular microenvironment. Research examining follistatin’s role in ovarian reserve — the size and quality of the remaining primordial follicle pool that determines reproductive lifespan — has illuminated fundamental mechanisms of reproductive ageing and premature ovarian insufficiency biology. This post examines the follistatin-activin-BMP axis in ovarian reserve research, with particular focus on follicle activation, AMH (Anti-Müllerian Hormone) regulation and the biology of ovarian ageing.

The Primordial Follicle Pool: Ovarian Reserve Biology

The ovarian reserve — the total pool of primordial follicles established during foetal development and progressively depleted throughout reproductive life — is the fundamental determinant of female reproductive lifespan. In humans, approximately 1–2 million primordial follicles are present at birth; by menarche this is reduced to 300,000–500,000, and by natural menopause (typically age 50–52) the pool is effectively exhausted at approximately 1,000 follicles. Of the total primordial follicle pool, fewer than 500 are ovulated over a reproductive lifetime — the vast majority are lost through atresia at various developmental stages.

The critical biology question that follistatin research addresses is how the rate of primordial follicle activation — the transition from quiescent primordial follicles to growing primary follicles — is regulated. This activation rate determines how rapidly the ovarian reserve is depleted and therefore how long reproductive capacity (and oestrogen production supporting bone density, cardiovascular and cognitive health) is maintained.

Follistatin and the Activin-BMP Signalling Network in Follicle Activation

Primordial follicle activation is suppressed by a complex network of inhibitory signals within the ovarian cortex, including:

• AMH (Anti-Müllerian Hormone): Produced by granulosa cells of growing follicles, AMH suppresses primordial follicle activation and inhibits FSH-induced follicular growth — creating a negative feedback loop that limits the number of follicles entering the growth phase simultaneously
• PTEN-PI3K-Akt pathway inhibition: In oocytes, PTEN (phosphatase and tensin homologue) suppresses PI3K-Akt-mTORC1 signalling that would drive cell growth and follicle activation; PTEN deletion in mice causes premature activation of the entire primordial follicle pool leading to rapid ovarian reserve depletion and premature ovarian failure
• BMP signals (BMP4, BMP7 from stromal cells; BMP15, GDF9 from oocytes): These TGF-β family members promote follicle survival and regulate activation rate through Smad1/5/8 signalling in granulosa cells

Follistatin binds activins and several BMPs with high affinity, neutralising their biological activity and preventing receptor engagement. Within the follicular microenvironment, follistatin expression levels determine the balance of activin/BMP signalling that governs granulosa cell function, FSH sensitivity, follicle survival and atresia susceptibility. Changes in follistatin production — either within the follicle itself or from surrounding stromal cells — can profoundly alter follicular dynamics.

AMH Regulation and the Follistatin Connection

Anti-Müllerian Hormone is the primary clinical biomarker of ovarian reserve in reproductive medicine, with serum AMH correlating with antral follicle count and predicting ovarian response to gonadotropin stimulation in ART (Assisted Reproductive Technology) contexts. The regulation of AMH expression in granulosa cells involves multiple factors including FSH, androgens and — critically — activin and follistatin signalling.

Activin A stimulates AMH expression in granulosa cells through Smad2/3 signalling, while follistatin neutralisation of activin reduces this AMH-stimulating drive. Research has examined how the follistatin:activin ratio in follicular fluid changes across the follicle development stages (primordial → primary → secondary → antral) and how this changing ratio modulates AMH secretion and FSH sensitivity at different developmental stages.

Understanding follistatin’s role in AMH regulation is relevant to research on premature ovarian insufficiency (POI), where accelerated follicle loss is associated with prematurely declining AMH, and to research on polycystic ovary syndrome (PCOS), where abnormally elevated AMH — associated with the excess small antral follicles of the polycystic ovary — reflects altered activin-follistatin-FSH regulatory dynamics.

FSH Sensitivity and Follicle Selection Research

The selection of a dominant follicle from the cohort of antral follicles entering each ovarian cycle depends on differential FSH sensitivity — the dominant follicle acquires greater FSH receptor expression and signalling capacity than its cohort members, enabling it to continue growing when FSH falls during the mid-follicular phase while others undergo atresia. Follistatin plays a role in this selection process by modulating the inhibin B/activin A ratio in individual follicles, which affects FSH receptor expression and downstream steroidogenesis.

Granulosa cells isolated from dominant versus subordinate follicles show different follistatin expression profiles, with dominant follicle granulosa cells typically producing more follistatin — creating a local environment that modulates activin-mediated signalling in a follicle-specific manner. Research using follicular fluid analysis, granulosa cell isolation, and in vitro follicle culture systems has characterised how follistatin concentrations within individual follicles correlate with their developmental competence and ultimate fate (dominant selection vs atresia).

Reproductive Ageing and Ovarian Reserve Depletion Research

Ovarian ageing is characterised by progressive reduction in both the quantity (follicle number) and quality (oocyte developmental competence) of the ovarian reserve. The mechanisms underlying age-related quality decline include:

• Mitochondrial dysfunction in oocytes — reduced ATP production, elevated ROS, impaired spindle assembly checkpoint — leading to meiotic errors (aneuploidy)
• Oxidative damage accumulation in oocytes and granulosa cells — elevated 8-OHdG, reduced antioxidant enzyme activity
• Altered follicular fluid composition — changing activin, follistatin, AMH and growth factor concentrations as the reserve depletes and follicle pool shifts toward smaller, less competent follicles
• Reduced granulosa cell responsiveness to gonadotropins and paracrine signals including the oocyte-secreted factors GDF9 and BMP15

Research examining how follistatin expression changes with ovarian ageing — in murine models of reproductive ageing, in aged bovine ovaries (a translatable large animal model), and in follicular fluid from older versus younger women in ART cycles — has provided mechanistic data on how the activin-follistatin balance shifts during reproductive ageing and whether this shift contributes to accelerated follicle activation and reserve depletion.

Premature Ovarian Insufficiency (POI) Research Models

Premature Ovarian Insufficiency — defined as loss of normal ovarian function before age 40 — affects approximately 1% of women and is characterised by elevated FSH, reduced AMH, menstrual irregularity and accelerated bone density loss from oestrogen deficiency. POI aetiology is heterogeneous, including autoimmune, genetic (FMR1 premutation, FOXL2 mutations), iatrogenic (chemotherapy, radiotherapy) and idiopathic causes. The activin-follistatin axis has been investigated in several POI research contexts:

• In autoimmune POI — where immune-mediated damage to granulosa cells impairs their production of follistatin and other regulatory factors — research has examined whether exogenous follistatin can partially protect residual follicles from immune-mediated activation and atresia
• In chemotherapy-induced ovarian insufficiency (cyclophosphamide models in rodents), research has examined how cytotoxic damage to the primordial follicle pool and ovarian stroma alters follistatin-activin dynamics and whether protection of this regulatory environment could reduce long-term fertility impairment
• Genetic models of FOXL2 mutation — the transcription factor essential for granulosa cell identity that regulates follistatin expression — have illuminated how granulosa cell follistatin production failure disrupts follicular dynamics

In Vitro Follicle Culture and Activation Research

In vitro activation (IVA) of dormant primordial follicles from ovarian cortical tissue has emerged as a research and clinical strategy for women with POI who wish to conceive. The approach involves surgical removal of ovarian cortical tissue, in vitro manipulation of follicle activation signalling (originally using PTEN inhibitors and PI3K activators), reimplantation of the activated tissue, and ovarian stimulation after follicle development. Research has examined whether follistatin modulation — reducing the activin-mediated brake on primordial follicle activation — could complement or extend IVA protocols.

Research using ovarian cortical tissue explant culture systems and primordial follicle isolation and activation assays has characterised how exogenous follistatin or activin alters activation rates, measuring primordial-to-primary follicle transition rate, granulosa cell proliferation (Ki-67), oocyte growth (diameter measurement), and follicle survival (propidium iodide exclusion in ex vivo culture).

Summary for Researchers

Follistatin ovarian reserve research examines the peptide’s role as a critical modulator of follicle activation rate through its high-affinity binding and neutralisation of activins and BMPs in the ovarian cortical microenvironment. The follistatin:activin ratio influences AMH expression and FSH sensitivity in developing follicles, regulates the speed of primordial follicle pool depletion, and changes during ovarian ageing in ways that may contribute to accelerated reserve loss. Research models including genetic HPG-deficient mice, POI models (autoimmune, chemotherapy-induced, FOXL2 mutation), ovarian cortical tissue explant culture for IVA research, and aged animal studies provide standardised platforms for investigating follistatin’s contribution to reproductive ageing and premature ovarian failure biology. AMH, antral follicle count, follicular fluid activin/follistatin ratios, primordial-to-primary follicle transition rates, and granulosa cell FSH receptor expression serve as primary endpoints characterising follistatin’s regulatory effects on ovarian reserve dynamics.

Research Use Only — UK Regulatory Notice: Follistatin is available for purchase in the United Kingdom for research and laboratory purposes only. It is not approved for human therapeutic use, is not a licensed medicinal product, and is not intended for use in clinical practice, human self-administration or veterinary treatment without appropriate regulatory authorisation. All research applications must comply with applicable UK legislation and institutional ethical oversight requirements.